Rigel reports R289 Phase 1b data: 33% RBC-TI in evaluable lower-risk MDS patients

RIGEL PHARMACEUTICALS INC

33 patients enrolled (median age 75, median 3 prior therapies); 61% high transfusion burden at baseline.
6/18 evaluable transfusion-dependent patients at doses ≥500 mg QD achieved RBC-TI >8 weeks; median duration 22.9 weeks.
R289 generally well tolerated; most common Grade 3/4 AEs: anemia (18%), neutropenia and pneumonia (each 15%).
Dose expansion phase ongoing; RP2D selection expected H2 2026.
R289 granted FDA Orphan Drug and Fast Track designations for MDS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.